Spruce Biosciences Reports Positive Long-Term Clinical Data for TA-ERT in Sanfilippo Syndrome Type B, Paving Way for FDA Approval
SPRB has more than doubled off its 52-week low of $4.275 on light trading volume (0.4× avg).
Summary
Spruce Biosciences presented positive long-term clinical data for its TA-ERT in Sanfilippo Syndrome Type B, showing durable reduction of heparan sulfate and preserved cognitive and motor outcomes, positioning it as a potential first-in-class therapy.
Key Events · Product Development and Regulatory · SPRB
-
Positive Long-Term Clinical Data
Spruce Biosciences announced long-term data (up to six years) for tralesinidase alfa enzyme replacement therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB), demonstrating rapid and durable reduction of heparan sulfate and preserved cognitive and non-cognitive outcomes.
-
Stabilization of Cognitive and Motor Skills
TA-ERT treatment stabilized cognitive function (Bayley-III Cognitive Raw Score), receptive and expressive communication, and fine and gross motor skills, contrasting with declines observed in untreated natural history patients.
-
Potential First-in-Class Therapy
The company highlights TA-ERT's potential as the first disease-modifying treatment option for MPS IIIB, a fatal condition with no currently approved therapies.
-
Clear Regulatory Path
The data strengthens confidence in advancing the program through a Biologics License Application (BLA) submission and potential U.S. FDA approval, with the possibility of accelerated approval.
Analysis · SPRB · Life Sciences
Spruce Biosciences announced highly significant long-term clinical data for its tralesinidase alfa enzyme replacement therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB). The data, presented at a major symposium, demonstrates TA-ERT's potential as the first disease-modifying treatment for this fatal genetic disorder. The sustained normalization of key biomarkers and preservation of cognitive and motor skills over six years, coupled with a favorable safety profile, significantly de-risks the program and strengthens the path towards a Biologics License Application (BLA) submission and potential FDA approval. This positive development is a critical catalyst for the company, given the high unmet medical need and the transformative potential for patients.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 40.7% of the 388 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SPRB was trading at $70.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.8M. The 52-week trading range was $4.28 to $240.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.